This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The Spring 2023 Quarterly Report provides summaries of most key patentlaw-related decisions from January 1, 2023 to March 31, 2023. We are excited to share Sheppard Mullin’s inaugural quarterly report on key Federal Circuit decisions. Click here to read more.
Image from here IP Court watchers will be pleased to know that the Delhi High Court’s IP Division has published the 2023-24 edition of its Annual Report ! Praharsh had written about the first report published in April 2023. appeals per 6 months) and 2023 (143/2=71.5 appeals per 6 months). Some Observations 1.
In Plant-e v Bioo the UPC provided its first decision addressing the doctrine of equivalents in patent infringement proceedings ( UPC_CFI_239/2023 ). Case details: Plant-based fuel cells The dispute in UPC_CFI_239/2023 concerned EP2137782 , owned by Plant-e Knowledge B.V.
Thank you to readers who voted for the IPKat book of the year awards 2023! Here are the nominees and winners: Best PatentLaw Book The nominations, in no particular order, were: • Der patentrechtliche Schutz von Daten und seine Grenzen; Landscheidt, by Fabian Landscheidt. The Unitary Patent Package and Unified Patent Court. .
In our annual review of developments in Canadian patentlaw, we considered over 60 patent decisions reported last year. This article highlights statutory changes and a selection of interesting points addressed in the reported decisions. By: Smart & Biggar
16, 2023) , the case addresses the Board’s anticipation and obviousness determinations in two IPRs (IPR2020-00002 and IPR2020-00004), where the Board held the claims in the challenged patents unpatentable as anticipated by, or obvious in view of, the asserted prior art. In Incept v. Palette Life Sciences 21-2063, 21-2065 (Fed.
by Dennis Crouch The following is my patentlaw exam from this past semester. EL has no evidence whether Buddy Strap intentionally copied his patent application or not, but he suspects they may have since they came to market after he published his application. What do you think?
by Dennis Crouch The Supreme Court is set to consider several significant patentlaw petitions addressing a range of issues from the application of obviousness standards, challenges to PTAB procedures, interpretation of joinder time limits IPR, to the proper scope patent eligibility doctrine.
Recently, the new Rules for the Implementation of PatentLaw (hereinafter referred to as "the Rules") has been approved and promulgated by the State Council, and will come into force on January 20, 2024. There are many amendments in the new Rules, and we have summarized the need-to-know points for your reference.
Recently, the new Rules for the Implementation of PatentLaw (hereinafter referred to as "the Rules") has been approved and promulgated by the State Council, and will come into force on January 20, 2024. There are many amendments in the new Rules, and we have summarized the need-to-know points for your reference.
The Court held that Amgen’s patent claims were invalid due to a lack of enablement, as they failed to provide adequate guidance for making and using the claimed antibodies. — (2023) ( 21-757_k5g1 ). Sanofi case, while significant, may not come as a surprise to those familiar with the evolution of patentlaw.
On December 11, 2023, the State Council of the People’s Republic of China announced its decision to amend the Implementing Regulations of the PatentLaw of the People’s Republic of China (the “2023 Regulations”), marking the first update in over 13 years since the last amendment in 2010.
We are pleased to see that Banaras Hindu University is organizing the 10th Mahamana Malaviya National Moot Court Competition, with the problem for this year’s competition surrounding patentlaw and incremental innovations. The competition is from 24th March- 26th March 2023. About the Organizer. About the Competition.
We are pleased to share Sheppard Mullin’s inaugural “Year in Review” report that collects and reports on most key patentlaw-related Federal Circuit decisions for 2023. This is a follow up to the quarterly report we introduced in Spring 2023, which was very well received.
25 sequence listing added to the pages of a divisional has now been issued ( OJ EPO 2023, A98 ). 26: Is it time for patent offices to enter the bioinformatic age? The topic of prior use has been elevated to the status of a referral to the Enlarged Board of Appeal ( G1/23 ). This is one to watch for 2024. Looking beyond ST.26:
In Thaler v Comptroller-General of Patents, Designs and Trade Marks [2023] UKSC 49, the UK Supreme Court ruled that AI cannot be an ‘inventor’ for the purposes of UK patentlaw.
Minerva and Hologic, competitors selling devices used for ablating uterine endometrial tissue, are notable for their dispute last year that gave the Supreme Court an opportunity to reassess an established patentlaw doctrine, assignor estoppel (reminiscent of the Court's review of the Federal Circuit's standard for obviousness in KSR Int'l v.
Supreme Court granted Amgen’s petition to review the “enablement requirement” of Section 112 of the Patent Act. The Court’s decision will likely come in the late second quarter of 2023 and could require significant strategic adjustments by patent owners and prosecutors. See generally Amgen Inc., Sanofi, No. 21-757 (U.S.
News & World Report – Best Lawyers “Best Law Firms” 2023 edition. Litigation – Patent . PatentLaw . Technology Law . Copyright Law . Trademark Law . In addition, the firm was nationally ranked in seven practice areas, including: . Litigation – Intellectual Property .
These were clearly watershed cases that dramatically changed the landscape of patentlaw and patent litigation. 2023) , highlights the current state of the law. Since 2012, almost 2,000 court decisions have referenced these cases along with 8,000+ PTAB decisions. The recent decision in Hawk Tech Sys.
As 2023 commences, it’s time for companies to review and take stock of their intellectual property assets. Such inventions may be protectable under federal patentlaws. An inventor must secure a patent application within a very short period of time to prevent the work from falling into the public domain.
I just gave a short (45 min) talk about the past year in patentlaw. See the slides here: Patent Year in Review. Vidal cert petition likely in January 2023. Patent Venue : Lots still happening in W.D.Tex. by Dennis Crouch. Broad IPR Estoppel : CalTech v. Broadcom/Apple. Pending before the Supreme Court.
Supreme Court, who died in December 2023, this article examines women's representation in the legal industry and in patentlaw. While an increasing number of women earn law degrees, women continue to be underrepresented as practicing attorneys and in leadership positions.
The Spring 2023 Quarterly Report provides summaries of most key patentlaw-related decisions from January 1, 2023 to March 31, 2023. We are excited to share Sheppard Mullin’s inaugural quarterly report on key Federal Circuit decisions. Click here to read more.
The Spring 2023 Quarterly Report provides summaries of most key patentlaw-related decisions from January 1, 2023 to March 31, 2023. We are excited to share Sheppard Mullin’s inaugural quarterly report on key Federal Circuit decisions. Please see full Publication below for more information.
The Present appeal involved three issues Issues 1 – The Scope and meaning of the term “inventor” in the 1977 Act The interpretation of Sections 7 and 13 in patentlaw leads to a clear conclusion: an inventor must be an individual, specifically a human. Mr.Thaler has explicitly disclaimed being the inventor in this context.
Introduction - Generative artificial intelligence (GenAI) has dominated headlines for nearly all of 2023 and demonstrated that it has the potential to disrupt the economic landscape by displacing jobs and creating remarkable efficiencies for business operations. By: Baker Donelson
On December 21, 2023, more than three years after the amendments to the PatentLaw in 2020 (2020 PatentLaw), the Implementation Regulations of the PatentLaw (Rules) and the Guidelines for Patent Examination (Guidelines) were issued and came into force on January 20, 2024.
Having freelanced as a patent research analyst, he developed an interest in patent prosecution and in exploring the Patents Act through various interpretative approaches. He is currently engaged in WIPO-Harvard Law School Course in PatentLaw and Global Public Health.
The past several years have brought a dizzying array of changes in patentlaw, between proposed new legislation, new USPTO filing procedures, and Supreme Court activity at a rate not seen in decades.
769 on December 21, 2023 to enact the Implementing Regulations of the PatentLaw (Amended in 2023) (hereinafter referred to as “the Implementing Regulations (Amended in 2023)”) as of January 20, 2024. China’s state council issued State Council Degree No. By: Linda Liu & Partners
In a noteworthy year for patentlaw, the U.S. Court of Appeals for the Federal Circuit issued several decisions that will shape the patent landscape and the Federal Rules of Evidence governing expert testimony were amended. Supreme Court and the U.S.
16, 2023), the case addresses the Board’s anticipation and obviousness determinations in two IPRs (IPR2020-00002 and IPR2020-00004), where the Board held the claims in the challenged patents unpatentable as anticipated by, or obvious in view of, the asserted prior art. In Incept v. Palette Life Sciences 21-2063, 21-2065 (Fed.
Defining Abnormal Patent Application Behaviors The “Regulations on the Norms of Patent Application Behavior (2023)” provide a clear definition of what constitutes abnormal patent application behaviors: Multiple Submissions: Submitting several applications with significantly identical content.
On January 26, 2023, the US Patent and Trademark Office (USPTO) conducted a public roundtable, during which various attorneys and industry experts discussed their thoughts on the intersection of patentlaw with non-fungible tokens (NFTs). By: ArentFox Schiff
In the Hatch-Waxman arena of patent litigation, the crisscross of patentlaws and FDA regulations is always in play. Avadel CNS Pharmaceuticals, LLC, 2023 WL 2198640 (Fed. 24, 2023), we see another iteration of this with respect to listing a method-of-use patent in the Orange Book.
There has been, since the turn of the century, a steady, seemingly inexorable trend towards limiting patent rights and focusing the application of U.S. patentlaw towards an emphasis on preventing innovators from obtaining patent rights broader than the minimum to which they may be entitled.
Thursday, July 20th, will offer another full day of sessions covering everything from responding to prior art rejections, to cultivating diversity in patentlaw, and best practices for PTAB appeals. My patentlaw update is Thursday morning. I hope to see you there! For more information and registration, click here.
Brussels Court of Appeal, 30 January 2023, Biogen v. Mylan In this typical preliminary injunction (PI) case, the Brussels Court of Appeal seems to have refined its case-law. Brussels Court of Appeal, 13 February 2023, Merck Sharp & Dohme v. But patience is rewarded. Is the wind shifting. ? Or (partly) back on track?
If such products were created by a human inventor, they could be eligible for patent protection. A human inventor serves as the central figure in the design of the patent system. The main rationale behind patentlaw is to reward and encourage the creative actions of creators. 362 [10] Lionel Bently et al.,
21-757) on Monday, March 27, 2023. The highly contentious question before the high court focuses what an applicant must show to meet the enablement requirement of patentlaw. The Supreme Court is set to hear oral arguments in Amgen, Inc. Sanofi (No. By: Bradley Arant Boult Cummings LLP
The Munich Local Division in SES vs Hanshow took a rather peculiar approach to claim interpretation, for which this Kat struggles to find basis in either EPO or national case law. The patent related to an electronic label for providing pricing information about a product to a consumer. T 439/22) (Jan 2024) Image credit : Midjourney
We organize all of the trending information in your field so you don't have to. Join 9,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content